T. Rowe Price Associates’s MyoKardia, Inc. Common Stock MYOK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-5,480,943
| Closed | -$747M | – | 2760 |
|
|
2020
Q3 | $747M | Buy |
5,480,943
+1,235,028
| +29% | +$131M | 0.09% | 235 |
|
|
2020
Q2 | $410M | Buy |
4,245,915
+657,401
| +18% | +$54.8M | 0.05% | 323 |
|
|
2020
Q1 | $168M | Buy |
3,588,514
+9,806
| +0.3% | +$628K | 0.03% | 453 |
|
|
2019
Q4 | $261M | Sell |
3,578,708
-58,847
| -2% | -$3.57M | 0.03% | 426 |
|
|
2019
Q3 | $190M | Buy |
3,637,555
+120,686
| +3% | +$6.42M | 0.03% | 460 |
|
|
2019
Q2 | $176M | Buy |
3,516,869
+132,654
| +4% | +$6.46M | 0.02% | 497 |
|
|
2019
Q1 | $176M | Buy |
3,384,215
+901,783
| +36% | +$41.5M | 0.03% | 500 |
|
|
2018
Q4 | $121M | Buy |
2,482,432
+14,024
| +0.6% | +$772K | 0.02% | 559 |
|
|
2018
Q3 | $161M | Buy |
2,468,408
+102,500
| +4% | +$6.03M | 0.02% | 543 |
|
|
2018
Q2 | $117M | Buy |
2,365,908
+368,147
| +18% | +$17.8M | 0.02% | 615 |
|
|
2018
Q1 | $97.5M | Buy |
1,997,761
+624,243
| +45% | +$32.5M | 0.02% | 656 |
|
|
2017
Q4 | $57.8M | Buy |
1,373,518
+555,393
| +68% | +$21.4M | 0.01% | 815 |
|
|
2017
Q3 | $35.1M | Buy |
818,125
+676,939
| +479% | +$21.6M | 0.01% | 991 |
|
|
2017
Q2 | $1.85M | Sell |
141,186
-94,397
| -40% | -$1.24M | ﹤0.01% | 1575 |
|
|
2017
Q1 | $3.1M | Buy |
235,583
+123,275
| +110% | +$1.58M | ﹤0.01% | 1487 |
|
|
2016
Q4 | $1.45M | Buy |
+112,308
| New | +$1.73M | ﹤0.01% | 1644 |
|
T. Rowe Price Associates's MYOK Position: Q4 2020 in Review
T. Rowe Price Associates sold out of MyoKardia, Inc. Common Stock (MYOK) in Q4 2020, closing a stake of 5,480,943 shares — an estimated $747M sold.
T. Rowe Price Associates first reported a position in MYOK in Q4 2016 and held it in 16 quarters. The position peaked at $747M in Q3 2020. 0 funds tracked by Wall St. Rank hold MYOK as of Q4 2020.
- T. Rowe Price Associates reported no remaining MyoKardia, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
- T. Rowe Price Associates sold 5,480,943 MyoKardia, Inc. Common Stock shares in Q4 2020, an estimated $747M.
- T. Rowe Price Associates first reported a position in MyoKardia, Inc. Common Stock in Q4 2016 and held it in 16 quarters.
- T. Rowe Price Associates's MyoKardia, Inc. Common Stock position peaked at $747M in Q3 2020.
- 0 funds tracked by Wall St. Rank held MyoKardia, Inc. Common Stock as of Q4 2020.
Based on T. Rowe Price Associates's 13F filing for Q4 2020, filed 16 Feb 2021.